Arch Biopartners Inc.

5 records totalling $9,805,265.00 CAD, from official Government of Canada open data.

Embed this chart

By department

Records

Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada
SIF Stream 1- R&D
FY 2020-2021
Canada

This project is to advance a lead therapeutic drug candidate through Phase II clinical trials to treat severe cases of COVID-19, specifically in the lungs, kidney and liver.

National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
FY 2022-2023
Canada

The project targets the prevention of acute organ inflammation injury in the lungs and kidneys of patients who have moderate to severe COVID-19 and other diseases. LSALT peptide is a novel drug candid...

National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
FY 2018-2019
Canada

LSALT is a peptide drug and a selective non-enzymatic dipeptidase-1 antagonist and prevents leukocyte adhesion to endothelial cells creating numerous indications for targeting inflammation in the cont...

National Research Council Canada | Conseil national de recherches Canada
FY 2011-2012
Canada
National Research Council Canada | Conseil national de recherches Canada
FY 2013-2014
Canada